FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Top Story

Amgen CEO: "I felt real economic pain"

What do you do when your biggest therapeutic earners are swooning, your stock price is down and analysts have turned scornful? Look for that silver lining. That was Amgen CEO Kevin Sharer's approach yesterday when he was confronted by an angry horde of shareholders at the company's annual meeting. Report

Syndicate content

Latest News

Eisai wins expert panel's approval for new sedative

May 8, 2008
Backed by a positive review from FDA staffers, an expert panel at the agency has recommended the agency approve Eisai's fospropofol disodium, a sedative designed for use in a number of procedures, Read more...
Tags: Eisai   Regulators   MGI Pharma   FDA  

FDA approves Lilly's ADHD drug Strattera

May 8, 2008
Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two Read more...
Tags: Eli Lilly   Strattera   ADHD   Thomas J. Spencer   Harvard Medical School   FDA approval   Adderall  

Traditional remedies offer opportunities, challenges

May 8, 2008
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
Tags: Traditional medicine   China   India   Paul Herrling   Nicholas Piramal   GlaxoSmithKline   pharmaceutical companies   Novartis   Merck  

Millipore touts its efforts to go green

May 8, 2008
The life sciences equipment maker Millipore is looking extra green today. The company announced plans to reduce its carbon footprint by 20 percent. To do that, the company plans to close some Read more...
Tags: Millipore   green initiatives   Martin Madaus   legislation  

SPOTLIGHT: FDA OKs expanded access for stem cell therapy

May 8, 2008
Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Read more...
Tags: Phase III  

ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...

May 8, 2008
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Tags: vaccine   FDA   central nervous system   Bill Wells   Genzyme   GlaxoSmithKline   Novartis   layoffs   antibodies  

Enzon spins off biotech ops into $150M enterprise

May 7, 2008
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
Tags: FDA   Jeffrey H. Buchalter   Craig Tooman   spin-off   Carl Icahn   Enzon Pharmaceuticals   Biogen Idec   Cancer   biotech news   pharmaceuticals  

California grants ignite a boom of lab construction

May 7, 2008
After four years of litigation and detailed planning, the first $271 million in facilities grants is just about ready to be doled out by the Read more...
Tags: stem cell   California   san francisco chronicle   Stem cell research   San Diego  

Novartis' China plans grew from science roundtables

May 7, 2008
PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the Read more...
Tags: Novartis   Paul Herrling   En Li   China   d center  

Astellas faces new delay for Advagraf approval

May 7, 2008
Japan's Astellas Pharma has run into a new roadblock in its pursuit of regulatory approval of Advagraf, its second generation version of the blockbuster transplant drug Prograf. The FDA has raised Read more...
Tags: Advagraf   Japan   FDA   Europe   Astellas Pharma   Regulators  

SPOTLIGHT: Mystery Mistral merger is off

May 7, 2008
Canada's Mistral Pharma says its proposed merger with an unnamed U.S. specialty pharma company will not be completed. As a result, its bridge financing deal has been canceled and management has Read more...
Tags: Mistral Pharma   merger   layoffs   Canada   pharmaceuticals  

C&L: Ajit Gill tapped to run Auspex

May 7, 2008
Ajit Gill has joined Auspex Pharmaceuticals as president and chief executive officer. In conjunction with the recent financing round, Pratik Shah, Ph.D., partner at Thomas, McNerney & Partners, Read more...
Tags: MacroGenics   MedImmune   CEO  

More news